Leerink is "cautiously optimistic" on Ultragenyx Pharma's (RARE) triheptanoin

August 24, 2016 9:08 AM EDT
Get Alerts RARE Hot Sheet
Price: $70.05 +2.43%

Rating Summary:
    16 Buy, 1 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade RARE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst, Joseph Schwartz, reiterated his Outperform rating on shares of Ultragenyx Pharma (NASDAQ: RARE) as he believes triheptanoin could be RARE’s second largest product behind KRN23 and have more impactful news flow over the near term.

In anticipation of upcoming LC-FAOD and Glut1 DS data in 2H16, the analyst took a closer look at the company-sponsored triheptanoin programs and is cautiously optimistic for positive data in both. He estimates a 60% probabilities of success.

The analyst stated "Based on triheptanoin’s underlying mechanism which resembles interventions that have worked before (MCT and KD), previous investigator data showing ~50% reduction in seizures on EEG, offset by small study size, patient demographics and the potential need for an additional (i.e. superiority to KD study) study, the analyst remain cautiously optimistic on triheptanoin prospects in Glut1 DS ahead of Ph2 seizure data in 2H".

No change to $85 PT.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $69.36 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment